Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsPediatric Oncology and HematologySolid TumorsProtocol groupIndolent LymphomasOther Solid Tumors (ped.)Plasma cell neoplasmsSarcomasTransplantationDiseaseAcute Promyelocytic LeukemiaEwing SarcomaHodgkin LymphomaMantle Cell LymphomaMultiple MyelomaNeuroblastomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbStem Cell Transplantation, AutologousSubgroupAge < 1 yearAge > 1 yearMYCN amplificationWeight < 10 kgICD10C40.-C41.-C47.-C81.-C82.-C82.7C82.9C83.1C83.3C90.-C90.0-C92.4-Z94.80MeSHHodgkin DiseaseNeuroblastomaPlasmacytomaSarcoma, EwingTransplantation, AutologousSequenceEWING 2012 Arm A VIDEEWING 2012 Arm B VDC/IETRIANGLEChemotherapyChemo-substanceCarboplatinEtoposide phosphateMelphalanChemo-substanceCarboplatinEtoposide phosphateMelphalanChemo-substanceCarboplatinEtoposide phosphateMelphalanChemo-substanceCarboplatinEtoposide phosphateMelphalanNo. Substances3 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionBendamustineBusulfanCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFilgrastimFosaprepitantGranisetronItraconazoleLevetiracetamMelphalanParacetamolPegfilgrastimPrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineBusulfanCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFilgrastimFosaprepitantGranisetronItraconazoleLevetiracetamMelphalanParacetamolPegfilgrastimPrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineBusulfanCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFilgrastimFosaprepitantGranisetronItraconazoleLevetiracetamMelphalanParacetamolPegfilgrastimPrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionBendamustineBusulfanCarmustineCiprofloxacinCotrimoxazoleCytarabineDexamethasoneDimetindenEtoposideFilgrastimFosaprepitantGranisetronItraconazoleLevetiracetamMelphalanParacetamolPegfilgrastimPrednisoloneThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances78911Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityHochdosis, bei autologer SZTStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationTherapy intentioncurativesupportiveRisksAnemia Hb below 8g/dlDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityIncrease AminotransferasesInfectionsMucositisMyositisNeutropeniaOral MucositisPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorAnderton JAttal MCaballero MDCaron HNDirksen UDreyling MKeil FLadetto MMata Fernandez CZulu SDiseaseAuto-SZT beim MMEwing-SarkomEwing Sarkom, ErstlinieMantelzelllymphom, Stadium II-IV, 18-65 J., transplantfähig, Erstlinie, ECOG 0-2Neuroblastom, Kinder unter 1 Jahr oder unter 10 kg und MYCN-Amplifikation, MegatherapieNeuroblastom, Kinder über 1 Jahr, MegatherapieNHL, HL, Rezidiv, fehlende Remission nach kurativer ChemotherapieNHL oder HL, auto-SZTprimär disseminiertes Ewing Sarkom, unter 50 J.Prämedikation der autologen StammzellinfusionRefraktäres oder rezidivierendes NHL oder HLOrigin3rd Medical Department for Haematology and Oncology, Hanusch Hospital, Vienna, AustriaDCOG NBL 2009Department of Hematology, Hospital Universitario Salamanca, SpanienDepartment of Translational Medicine, University of Eastern Piedmont, Novara, ItalyEBMT, Cancer Services, Royal Free Hospital, London, UKEuro-E.W.I.N.G.99 and Ewing-2008Euro Ewing 2012 protocolFunctional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (EWING 2008)Institut Universitaire du Cancer de Toulouse-Oncopole and Service d'Epidemiologie, Centre Hospitalier et Universitaire de Toulouse, Toulouse, FranceLMU University Hospital, Munich, Germany, TRIANGLE StudyProtokolle in Überarbeitung 11 protocols foundBEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID280 V2.2)Revision: BeEAM - Bendamustine 200 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID879 V1.1)Revision: Busulfan 0.8 / Melphalan 140, Autologous Stem Cell Transplantation (PID571 V1.2)Revision: Busulfan 3.2 / Melphalan 140, Autologous Stem Cell Transplantation (PID76 V1.1)Revision: Melphalan 100, Multiple Myeloma, Autologous Stem Cell Transplantation (PID528 V2.3)Revision: Melphalan 140 / Treosulfan 12, Ewing Sarcoma, Autologous Stem Cell Transplantation (PID1396 V2.2)Revision: PAED Melphalan 45 / Etoposide Phosphate 40 / Carboplatin 500, Neuroblastoma, autologous Stem Cell Transplantation (PID2887 V1.1)Revision: PAED Melphalan 1.5 / Etoposide Phosphate 40 / Carboplatin 16.6, Neuroblastoma, Stem Cell Transplantation, Autologous (PID2888 V1.1)Stem cell infusion, Autologous Stem Cell Transplantation (PID614 V2.1)Revision: TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 140, Autologous Stem Cell Transplantation (PID406 V2.1)Revision: THAM - Cytarabine 1500 / Melphalan 140 / TBI, Mantle Cell Lymphoma, Autologous Stem Cell Transplantation (PID3165 V1.1)
